Welcome
IP Law News

Ocular Therapeutix Sees Red Over Eye Surgery Device Patent Claim

Dec. 17, 2018, 6:19 PM

Mati Therapeutics Inc. is unfairly trying to get Ocular Therapeutix Inc. to pay up to avoid a patent infringement suit on its eye surgery device Dextenza, a new lawsuit claims.

Biopharmaceutical company Ocular said Mati alleges Ocular’s Dextenza—a device that the Food and Drug Administration approved less than a month ago—infringes a patent Mati owns. But Ocular—in a suit filed Dec. 14 in federal court in Delaware—says it doesn’t infringe and Mati’s allegations are no more than a money grab.

Ocular is asking the court to rule Dextenza, a drug-eluting intracanalicular insert for treating post-surgical eye pain and other eye...

To read the full article log in. To learn more about a subscription click here.